Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

Tamami Okamoto, Sho ichi Yamagishi, Yosuke Inagaki, Shinjiro Amano, Kohachiro Koga, Riichiro Abe, Masayoshi Takeuchi, Shigeaki Ohno, Akihiko Yoshimura, Zenji Makita

Research output: Contribution to journalArticle

238 Citations (Scopus)

Abstract

We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE)-overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.

Original languageEnglish
Pages (from-to)1928-1930
Number of pages3
JournalThe FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Volume16
Issue number14
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Endothelial cells
Endothelial Cells
Transcription Factor AP-1
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Glycols
cerivastatin
Angiopoietin-2
Glyceraldehyde
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pericytes
Messenger RNA
Curcumin
Medical problems
Growth
Sugars
Transcriptional Activation
Blood Vessels
Cultured Cells

Cite this

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. / Okamoto, Tamami; Yamagishi, Sho ichi; Inagaki, Yosuke; Amano, Shinjiro; Koga, Kohachiro; Abe, Riichiro; Takeuchi, Masayoshi; Ohno, Shigeaki; Yoshimura, Akihiko; Makita, Zenji.

In: The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 16, No. 14, 2002, p. 1928-1930.

Research output: Contribution to journalArticle

Okamoto, T, Yamagishi, SI, Inagaki, Y, Amano, S, Koga, K, Abe, R, Takeuchi, M, Ohno, S, Yoshimura, A & Makita, Z 2002, 'Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.', The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol. 16, no. 14, pp. 1928-1930.
Okamoto, Tamami ; Yamagishi, Sho ichi ; Inagaki, Yosuke ; Amano, Shinjiro ; Koga, Kohachiro ; Abe, Riichiro ; Takeuchi, Masayoshi ; Ohno, Shigeaki ; Yoshimura, Akihiko ; Makita, Zenji. / Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. In: The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2002 ; Vol. 16, No. 14. pp. 1928-1930.
@article{90b9f7875eb7493eb91e0729bfea632e,
title = "Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.",
abstract = "We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE)-overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.",
author = "Tamami Okamoto and Yamagishi, {Sho ichi} and Yosuke Inagaki and Shinjiro Amano and Kohachiro Koga and Riichiro Abe and Masayoshi Takeuchi and Shigeaki Ohno and Akihiko Yoshimura and Zenji Makita",
year = "2002",
language = "English",
volume = "16",
pages = "1928--1930",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "14",

}

TY - JOUR

T1 - Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

AU - Okamoto, Tamami

AU - Yamagishi, Sho ichi

AU - Inagaki, Yosuke

AU - Amano, Shinjiro

AU - Koga, Kohachiro

AU - Abe, Riichiro

AU - Takeuchi, Masayoshi

AU - Ohno, Shigeaki

AU - Yoshimura, Akihiko

AU - Makita, Zenji

PY - 2002

Y1 - 2002

N2 - We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE)-overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.

AB - We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE)-overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=0036884617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036884617&partnerID=8YFLogxK

M3 - Article

C2 - 12368225

AN - SCOPUS:0036884617

VL - 16

SP - 1928

EP - 1930

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 14

ER -